ONC206 for Brain Tumors
Phase 1
208
about 5.9 years
2–21
4 sites in CA, GA, MI +1
What this study is about
This trial is testing ONC206, a new drug, alone or with radiation therapy, to treat brain tumors. The goal is to find the best dose of ONC206 and see if it can stop cancer cells from growing in patients with newly diagnosed or recurrent diffuse midline gliomas and other types of recurrent malignant CNS tumors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Standard of Care Radiation Therapy
- 2.Take ONC206
- 3.Undergo Optional Proton (1H) MR spectroscopy (MRS)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Maximum tolerated dose (MTD) of ONC206, Proportion of participants with dose-limiting toxicities (DLT)
Secondary: Area under the curve (AUC) of ONC206, Elimination half-life (t1/2) of ONC206, Mean Total body clearance (CL) for ONC206, Mean corresponding time (Tmax) of ONC206, Mean maximum concentration (Cmax) of ONC206
radiation
Oncology